Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)
Mairéad G. McNamara, John Bridgewater, Daniel H. Palmer, et al.
The Oncologist (2020) Vol. 26, Iss. 4, pp. e669-e678
Open Access | Times Cited: 19

Showing 19 citing articles:

Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Alessandra Elvevi, Alice Laffusa, Miki Scaravaglio, et al.
Annals of Hepatology (2022) Vol. 27, Iss. 5, pp. 100737-100737
Open Access | Times Cited: 93
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100335-100335
Open Access | Times Cited: 83
Rational development of combination therapies for biliary tract cancers
James J. Harding, Danny N. Khalil, Luca Fabris, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 217-228
Closed Access | Times Cited: 41
New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy
Ezequiel Mauro, Joana Ferrer, Tamara Saurí, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1244-1244
Open Access | Times Cited: 25
A phase III randomised study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
Jennifer J. Knox, Mairéad G. McNamara, I. Bazin, et al.
Journal of Hepatology (2025)
Closed Access | Times Cited: 1
Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
Sandra Kang, Bassel F. El‐Rayes, Mehmet Akce
Cancers (2022) Vol. 14, Iss. 7, pp. 1748-1748
Open Access | Times Cited: 24
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Gaël S. Roth, Cindy Neuzillet, Matthieu Sarabi, et al.
European Journal of Cancer (2022) Vol. 179, pp. 1-14
Open Access | Times Cited: 18
Update on Chemoresistance Mechanisms to First-Line Chemotherapy for Gallbladder Cancer and Potential Reversal Strategies
Jinbao Lai, Songlin Yang, Zhuying Lin, et al.
American Journal of Clinical Oncology (2023) Vol. 46, Iss. 4, pp. 131-141
Open Access | Times Cited: 9
Drug resistance and new therapies in gallbladder cancer
Yuxin Sun, Xiaoxuan Li, Haihong Cheng, et al.
Drug Discoveries & Therapeutics (2023) Vol. 17, Iss. 4, pp. 220-229
Open Access | Times Cited: 7
Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
José J.G. Marı́n, Paula Sanchon-Sanchez, Candela Cives-Losada, et al.
Cancers (2021) Vol. 13, Iss. 10, pp. 2358-2358
Open Access | Times Cited: 14
Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report
Lisha Li, Dandan Yu, Jinru Yang, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Extrahepatic cholangiocarcinoma: Current status of endoscopic approach and additional therapies
Alina Tanțău, Alina Mândruţiu, Anamaria Pop, et al.
World Journal of Hepatology (2021) Vol. 13, Iss. 2, pp. 166-186
Open Access | Times Cited: 9
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)”
Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi
The Oncologist (2021) Vol. 26, Iss. 5, pp. e902-e902
Open Access | Times Cited: 6
Targeting inhibitor of apoptosis proteins (IAPs) with IAP inhibitors sensitises malignant rhabdoid tumour cells to cisplatin
Rachel Coyle, Maureen J. O’Sullivan, Daniela M. Zisterer
Cancer Treatment and Research Communications (2022) Vol. 32, pp. 100579-100579
Open Access | Times Cited: 4
Combination Therapies for Advanced Biliary Tract Cancer
Weifeng Zeng, Ruiqi Mao, Zhanguo Zhang, et al.
Journal of Clinical and Translational Hepatology (2022) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 4
Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase
Katsuya Nagaoka, Xuewei Bai, Dan Liú, et al.
Cancer Letters (2023) Vol. 580, pp. 216493-216493
Closed Access | Times Cited: 2
Current options and future directions of systemic therapy for advanced biliary tract cancer
Maria Giuseppina Prete, Antonella Cammarota, Antonio D’Alessio, et al.
Exploration of Targeted Anti-tumor Therapy (2021) Vol. 2, Iss. 5
Open Access | Times Cited: 1
Combining of chemotherapy with targeted therapy for advanced biliary tract cancer: A systematic review and meta-analysis
Xue‐Song Bai, Shengnan Zhou, Yi-Qun Jin, et al.
World Journal of Gastrointestinal Oncology (2022) Vol. 14, Iss. 10, pp. 2061-2076
Open Access
In Reply
Mairéad G. McNamara, Juan W. Valle
The Oncologist (2021) Vol. 26, Iss. 5, pp. e903-e904
Open Access
Page 1

Scroll to top